Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2011 (2011), Article ID 405724, 8 pages
http://dx.doi.org/10.1155/2011/405724
Clinical Study

One-Year Outcomes Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Results of a Prospective and Retrospective Observational Multicentre Study

1St. Erik's Eye Hospital, Karolinska Institutet, Polhemsgatan 50, 11282 Stockholm, Sweden
2Department of Ophthalmology, Lund University Hospital, 22185 Lund, Sweden
3Department of Ophthalmology, Helsingborg Hospital, 25187 Helsingborg, Sweden
4Department of Ophthalmology, Ryhov Hospital, 55185 Jönköping, Sweden
5Department of Ophthalmology, Södersjukhuset, 11883 Stockholm, Sweden
6Department of Ophthalmology, Örebro University Hospital, 70185 Örebro, Sweden
7Medical Department, Novartis Sweden AB, 18311 Täby, Sweden

Received 3 August 2011; Accepted 7 September 2011

Academic Editor: G. L. Spaeth

Copyright © 2011 Lars Hjelmqvist et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Pascolini, S. P. Mariotti, G. P. Pokharel et al., “2002 Global update of available data on visual impairment: a compilation of population-based prevalence studies,” Ophthalmic Epidemiology, vol. 11, no. 2, pp. 67–115, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Congdon, B. O'Colmain, C. C. Klaver et al., “Causes and prevalence of visual impairment among adults in the United States,” Archives of Ophthalmology, vol. 122, no. 4, pp. 477–485, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Bunce and R. Wormald, “Causes of blind certifications in England and Wales: April 1999–March 2000,” Eye, vol. 22, no. 7, pp. 905–911, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. W. Smith, J. Assink, R. Klein et al., “Risk factors for age-related macular degeneration: pooled findings from three continents,” Ophthalmology, vol. 108, no. 4, pp. 697–704, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. L. M. Weih, M. R. VanNewkirk, C. A. McCarty, and H. R. Taylor, “Age-specific causes of bilateral visual impairment,” Archives of Ophthalmology, vol. 118, no. 2, pp. 264–269, 2000. View at Google Scholar · View at Scopus
  6. E. S. Gragoudas, A. P. Adamis, E. T. Cunningham Jr. et al., “Pegaptanib for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 351, no. 27, pp. 2805–2816, 2004. View at Publisher · View at Google Scholar
  7. N. Ferrara, L. Damico, N. Shams, H. Lowman, and R. Kim, “Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration,” Retina, vol. 26, no. 8, pp. 859–870, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. P. J. Rosenfeld, D. M. Brown, J. S. Heier et al., “Ranibizumab for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1419–1431, 2006. View at Publisher · View at Google Scholar
  9. N. M. Bressler, T. S. Chang, J. T. Fine et al., “Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial,” Archives of Ophthalmology, vol. 127, no. 1, pp. 13–21, 2009. View at Publisher · View at Google Scholar
  10. S. P. Harding, “Neovascular age-related macular degeneration: decision making and optimal management,” Eye, vol. 24, no. 3, pp. 497–505, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Mitchell, J. F. Korobelnik, P. Lanzetta et al., “Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials,” British Journal of Ophthalmology, vol. 94, no. 1, pp. 2–13, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. D. M. Brown and C. D. Regillo, “Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients,” American Journal of Ophthalmology, vol. 144, no. 4, pp. 627–637, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. A. E. Fung, G. A. Lalwani, P. J. Rosenfeld et al., “An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration,” American Journal of Ophthalmology, vol. 143, no. 4, pp. 566–583, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Spielberg and A. Leys, “Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 246, no. 7, pp. 943–956, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. I. Mantel, L. Zografos, and A. Ambresin, “Early clinical experience with ranibizumab for occult and minimally classic neovascular membranes in age-related macular degeneration,” Ophthalmologica, vol. 222, no. 5, pp. 321–323, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. B. J. Ernst, A. J. Barkmeier, and L. Akduman, “Optical coherence tomography-based intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration,” International Ophthalmology, vol. 30, no. 3, pp. 267–270, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Y. Cohen, L. Dubois, R. Tadayoni et al., “Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting,” American Journal of Ophthalmology, vol. 148, no. 3, pp. 409–413, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Parravano, F. Oddone, M. Tedeschi et al., “Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration patients treated with ranibizumab,” Retina, vol. 329, no. 3, pp. 329–334, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Michalova, S. S. Wickremasinghe, T. H. Tan et al., “Ranibizumab treatment for neovascular age-related macular degeneration: from randomized trials to clinical practice,” Eye, vol. 23, no. 8, pp. 1633–1640, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Querques, S. Azrya, D. Martinelli et al., “Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting,” British Journal of Ophthalmology, vol. 94, no. 3, pp. 292–296, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Dadgostar, A. A. C. M. Ventura, J. Y. Chung, S. Sharma, and P. K. Kaiser, “Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration,” Ophthalmology, vol. 116, no. 9, pp. 1740–1747, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. D. F. Martin, M. G. Maguire, G. S. Ying et al., “Ranibizumab and bevacizumab for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 364, no. 20, pp. 1897–1908, 2011. View at Publisher · View at Google Scholar
  23. C. M. Mangione, P. P. Lee, P. R. Gutierrez et al., “Development of the 25-item national eye institute visual function questionnaire,” Archives of Ophthalmology, vol. 119, no. 7, pp. 1050–1058, 2001. View at Google Scholar
  24. D. Sheskin, Handbook of Parametric and Nonparametric Statistical Procedures, CRC Press, Boca Raton, Fla, USA, 1996.
  25. D. M. Brown, M. Michels, P. K. Kaiser et al., “Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study,” Ophthalmology, vol. 116, no. 1, pp. 57–65, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Funk, D. Karl, M. Georgopoulos et al., “Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab,” Ophthalmology, vol. 116, no. 12, pp. 2393–2399, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. C. D. Regillo, D. M. Brown, P. Abraham et al., “Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1,” American Journal of Ophthalmology, vol. 145, no. 2, pp. 239–248, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Abraham, H. Yue, and L. Wilson, “Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2,” American Journal of Ophthalmology, vol. 150, no. 3, pp. 315.e1–324.e1, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. O. P. Gupta, G. Shienbaum, A. H. Patel, C. Fecarotta, R. S. Kaiser, and C. D. Regillo, “A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration: clinical and economic impact,” Ophthalmology, vol. 117, no. 11, pp. 2134–2140, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Bolz and U. Schmidt-Erfurth, “Ranibizumab EXCITE study: exploring the value of optical coherence tomography for the management of ranibizumab therapy in age-related macular degeneration,” in Proceedings of the 8th European Society of Retina Specialists Congress (EURETINA '08), Vienna, Austria, May 2008.
  31. G. A. Lalwani, P. J. Rosenfeld, A. E. Fung et al., “A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study,” American Journal of Ophthalmology, vol. 148, no. 1, pp. 43–58, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Engelbert, S. A. Zweifel, and K. B. Freund, ““Treat and extend” dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation,” Retina, vol. 29, no. 10, pp. 1424–1431, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. F. G. Holz, J. F. Korobelnik, P. Lanzetta et al., “The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model,” Investigative Ophthalmology & Visual Science, vol. 51, no. 1, pp. 405–412, 2010. View at Google Scholar · View at Scopus
  34. S. P. Rothenbuehler, D. Waeber, C. K. Brinkmann, S. Wolf, and U. E. K. Wolf-Schnurrbusch, “Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration,” American Journal of Ophthalmology, vol. 147, no. 5, pp. 831–837, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. P. K. Kaiser, “Prospective evaluation of visual acuity assessment: a comparison of Snellen versus ETDRS charts in clinical practice (An AOS Thesis),” Transactions of the American Ophthalmological Society, vol. 107, pp. 311–324, 2009. View at Google Scholar · View at Scopus
  36. D. S. Boyer, J. S. Heier, D. M. Brown, S. F. Francom, T. Ianchulev, and R. G. Rubio, “A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration,” Ophthalmology, vol. 116, no. 9, pp. 1731–1739, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. S. J. Bakri, M. R. Snyder, J. M. Reid, J. S. Pulido, M. K. Ezzat, and R. J. Singh, “Pharmacokinetics of Intravitreal ranibizumab (Lucentis),” Ophthalmology, vol. 114, no. 12, pp. 2179–2182, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Gaudreault, D. Fei, J. C. Beyer et al., “Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits,” Retina, vol. 27, no. 9, pp. 1260–1266, 2007. View at Publisher · View at Google Scholar · View at Scopus